ArticleJournal of molecular histology2025
METTL5-mediated m6A modification of UBE3C promotes osteosarcoma progression by suppressing ferroptosis via inducing AHNAK ubiquitination.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Decoding osteosarcoma pathogenesis: the pivotal influence of mEpigenetics · 2026Review
- Targeting the METTL5-MGST1 axis for cancer therapy: molecular mechanisms and therapeutic implications.Molecular biology reports · 2026Review
- Significance of Methyltransferase-like 5 Expression in Oral Squamous Cell Carcinoma.International dental journal · 2026Article
- Bidirectional regulation of the ubiquitin-RNA modification axis in cancer.Frontiers in oncology · 2026Review
- METTL5 in physiology and pathology: mechanisms and implications.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ferroptosis, marked by iron-dependent lipid peroxidation, emerges as a promising approach for osteosarcoma (OS) intervention due to its tumor susceptibility. Ubiquitination is a key post-translational modification involved in regulating cell ferroptosis and is closely linked to cancer development. Ubiquitin protein ligase E3C (UBE3C), an E3 ubiquitin ligase plays a carcinogenic role in several cancers. However, the roles and molecular mechanisms of UBE3C in OS cell ferroptosis remain unclear. UBE3C level was enhanced in OS tissues and cells, and UBE3C depletion impeded OS cell proliferation, migration, and invasion and accelerated ferroptosis. Moreover, Fer-1 administration counteracted the inhibitory impact of UBE3C silencing on the malignant behavior of U2OS and 143B cells. Mechanistically, UBE3C promoted the ubiquitination and degradation of AHNAK in U2OS and 143B cells. AHNAK counteracted the effect of UBE3C on promoting cell proliferation, migration, and invasion and inhibiting cell ferroptosis. Further, METTL5-mediated m6A modification enhanced UBE3C mRNA stability by enabling YTHDF1 to bind and protect the modified mRNA from degradation. METTL5 addition inhibited AHNAK level which was abolished by UBE3C silencing. Our work uncovered a new METTL5-YTHDF1-UBE3C-AHNAK signaling axis regulating ferroptosis and driving OS progression. Targeting this axis offers a promising approach to enhance ferroptosis sensitivity against OS.
Indexed as
Identifiers
40696164What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.